Collaborations at SphingoTec
SphingoTec is committed to transforming critical care diagnostics through strategic collaborations, with a strong focus on out-licensing and partnerships with diagnostics and pharmaceutical companies. Our approach leverages our innovative biomarker portfolio to accelerate the development and global adoption of next-generation diagnostic solutions.
Biomarker out-licensing
SphingoTec offers out-licensing opportunities for its proprietary, clinically validated biomarkers to diagnostics and medical technology companies worldwide. By partnering with SphingoTec, licensees gain access to innovative biomarker assays addressing diagnostically underserved acute and critical care conditions, such as acute kidney injury, sepsis, and acute heart failure
Pharma Collaborations
Our diagnostic solutions address critical disease pathways, for which other companies develop treatments. The use of biomarkers to identify treatment responders and non-responders becomes increasingly important. Our biomarkers can provide a solution for enrichment and increased efficacy strategies in critical care drug discovery to de-risk drug developments.